Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galectin closes rights offering, raises $44.5mm

Executive Summary

Galectin Therapeutics Inc. (chronic liver and skin diseases and cancer) raised $44.5mm through a rights offering which resulted in the issuance of 10.4mm common shares at $4.28 per share. Investors also received seven-year warrants to purchase 2.6mm shares at $7. A portion of the proceeds will support a Phase III trial with GRMD02 in nonalcoholic steatohepatitis patients without esophageal varices.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Other

Related Companies